| T766 |
0-1081 |
Sentence |
denotes |
Tang et al. (2020) [35] Multicenter, open-label, randomized controlled trial150 mild/moderate or severe COVID-19 infected patients HCQ group -> SOC+ HCQ (200 mg daily for three days followed by a maintained dose of 800 mg daily)Control group-> SOC2 for mild/moderate patients and 3 weeks for severe patients Within 28 days of treatment, the probability of negative conversion of SARS-CoV-2 was 85.4% (95% CI 73.8% to 93.8%) in the HCQ + SOC group and 81.3% (95% CI 71.2% to 89.6%) in the SOC group.No significant differences in the median time to negative conversion were found between the HCQ + SOC group (8 days, 95% CI 5 to 10 days) and SOC group (7 days, 95% CI 5 to 8 days).No difference in PCRnegativity was found between two groups at day 4, 7, 10, 14, or 21.No significant differences in the meantime of clinical symptom alleviation were found between the two groups (19 days for HCQ + SOC vs. 21 days for SOC) Adverse events noted in 30% of the HCQ group compared to 8.8% ofcontrol groupThe most common adverse effect was diarrhea (10%).One patient had blurred vision. |
